循环性肿瘤细胞检测套件市场报告：2031 年趋势、预测与竞争分析

全球循环性肿瘤细胞检测套件市场前景看好，医院和诊所市场都存在机会。预计到 2031 年全球循环性肿瘤细胞检测套件市场规模将达到 1,6,992 亿美元，2025-2031 年期间的复合年增长率为 3.5%。该市场的主要驱动力是癌症研究和诊断的进步以及全球癌症患者数量的增加。

• Lucintel 预测，上皮癌类型将在预测期内经历最高的增长。
• 从用途来看，医院和诊所预计将出现强劲成长。
• 根据地区，预计北美将在预测期内实现最高成长。

循环性肿瘤细胞检测套件市场的策略性成长机会

循环性肿瘤细胞(CTC) 检测套件市场呈现众多策略性成长机会，这得益于技术进步、癌症发生率上升以及向个人化医疗的转变。公司可以利用这些趋势来增强其产品并扩大其市场占有率。

• 扩展到新兴市场：亚洲、非洲和拉丁美洲的新兴市场为 CTC 检测试剂套件带来了巨大的成长机会。癌症发病率的上升和医疗保健投资的增加正在推动对先进诊断解决方案的需求。公司可以透过建立本地伙伴关係并根据当地需求调整产品来进入这些市场，确保更广泛地获得 CTC 技术。
• 人工智慧的整合：将人工智慧（AI）融入CTC检测过程代表着一个变革性的成长机会。人工智慧可以增强资料分析和解释，使 CTC 识别更快、更准确。开发人工智慧解决方案的公司可以脱颖而出，为肿瘤学家提供宝贵的见解，从而推动更好的患者管理和治疗结果。
• 组合诊断的发展：将 CTC 检测与其他生物标记评估相结合的组合诊断试剂套件的开发趋势日益增长。这种综合方法可以更全面地了解患者的肿瘤生物学和治疗反应。在这一领域进行创新的公司可以提高其产品的效用，并吸引寻求更多资讯诊断工具的医疗保健提供者。
• 注重研发：CTC检测技术的进步需要研发投入。优先考虑研发的公司可以开发出具有更高灵敏度、特异性和易用性的下一代套件。这项专注的努力将带来液态切片技术的突破，并使公司成为快速发展的市场的领导者。
• 与监管机构合作以加速核准：主动与监管机构合作可以帮助加速新型 CTC 检测套件的核准流程。有效应对监管环境的公司能够更快地将创新产品推向市场。这种策略参与还可以促进合作机会并提高产品在行业内的可信度和认可度。

循环性肿瘤细胞检测套件市场的策略性成长机会，例如向新兴市场的扩张、人工智慧整合、竞争性诊断、研发投资以及参与监管环境，将使公司在竞争激烈且不断变化的环境中取得成功。

循环性肿瘤细胞检测试剂套件市场驱动因素与挑战

循环性肿瘤细胞(CTC) 检测套件市场受到推动成长的几个关键驱动因素以及公司必须应对的挑战的影响。了解这些因素对于寻求在竞争环境中取得成功的相关人员至关重要。

推动循环性肿瘤细胞检测套件市场发展的因素有：

• 癌症发生率上升：全球癌症发生率上升是 CTC 检测套件市场的主要驱动力。随着越来越多的人被诊断出患有各种类型的癌症，对能够早期发现和监测的有效诊断工具的需求也越来越大。这些日益增长的需求正在推动医疗保健提供者采用先进的 CTC 技术，扩大市场机会。
• 技术进步：微射流和下一代定序等不断的技术创新正在推动 CTC 检测市场的发展。这些进步提高了检测试剂套件的敏感度和特异性，使其在临床应用中更加可靠。利用最尖端科技的公司能够提供优质的产品，吸引医疗专业人员和患者。
• 向个人化医疗转变：个人化医疗的日益增长趋势正在推动对 CTC 检测套件的需求。肿瘤学家越来越多地寻求根据个别患者情况制定个人化治疗方案，而 CTC 分析为这种个人化治疗方案提供了重要的见解。对个人化治疗的关注为 CTC 检测领域的公司创造了丰厚的利润机会。
• 增加对癌症研究的投资：对癌症研究和开发的大量投资进一步推动了 CTC 检测市场的发展。政府机构、私人公司和製药公司正在投入资源进行创新癌症诊断，包括 CTC 技术。资金的涌入正在刺激合作研究并加速新的有效诊断解决方案的发展。
• 认识液态切片的好处：提高对液态切片好处的认识是 CTC 检测试剂套件市场发展的关键驱动力。患者和医疗保健提供者认识到非侵入性检测方法的好处，可以减少对传统组织切片检查的需求。随着液态切片知识的传播，CTC 检测试剂套件的需求预计会增加。

循环性肿瘤细胞检测套件市场的挑战如下：

• 技术成本高：CTC 检测试剂套件市场面临的主要挑战之一是先进技术带来的高成本。许多 CTC 检测试剂套件由于开发和製造过程复杂而昂贵。高成本限制了它们的使用，特别是在资源贫乏的环境中，并影响了它们的广泛采用。
• 监管障碍：对于希望将新的 CTC 检测产品推向市场的公司来说，了解监管环境可能是一个挑战。严格的核准流程和不同地区的不同监管要求会减慢产品上市时间并增加营运成本。公司必须投入时间和资源来确保遵守这些法规，进而影响其竞争力。
• 竞争和市场饱和：随着越来越多的公司进入 CTC 检测市场，竞争和市场饱和方面存在挑战。随着越来越多的公司提供类似的产品，每家公司对其产品的差异化变得非常重要。这种竞争压力可能导致价格战，影响利润率，并需要不断创新才能维持市场相关性。

循环性肿瘤细胞检测套件市场受到癌症发病率上升、技术进步、个人化医疗趋势、研究投入增加以及对液态切片益处的认可等因素的推动，但也面临着高成本、监管障碍和激烈竞争等挑战。

目录

第一章执行摘要

第二章全球循环性肿瘤细胞检测套件市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球循环性肿瘤细胞检测套件市场趋势（2019-2024）及预测（2025-2031）
• 全球循环性肿瘤细胞检测套件市场（按类型）
  • 上皮
  • 插页式广告
  • 上皮间质型
• 全球循环性肿瘤细胞检测套件市场（按应用）
  • 医院
  • 诊所
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 循环性肿瘤细胞检测套件市场（按地区）
• 北美循环性肿瘤细胞检测套件市场
• 欧洲循环性肿瘤细胞检测套件市场
• 亚太地区循环性肿瘤细胞检测套件市场
• 世界其他地区循环性肿瘤细胞检测套件市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球循环性肿瘤细胞检测套件市场成长动力（按类型）
  • 全球循环性肿瘤细胞检测套件市场的成长机会（按应用）
  • 区域循环性肿瘤细胞检测套件市场的成长机会
• 全球循环性肿瘤细胞检测套件市场的新趋势
• 战略分析
  • 新产品开发
  • 全球循环性肿瘤细胞检测套件市场产能扩张
  • 全球循环性肿瘤细胞检测套件市场的併购和合资企业
  • 认证和许可

第七章主要企业简介

• Menarini Silicon Biosystems
• ZHIHUI MEDICAL
• Watson BIoTech
• NovoBIoTechnology
• GENO
• BioMab
• STEMCELL Technologies

The future of the global circulating tumor cell detection kit market looks promising, with opportunities in the hospital and clinic markets. The global circulating tumor cell detection kit market is expected to reach an estimated $1699.2 billion by 2031, with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are advancements in cancer research and diagnostics and the increasing prevalence of cancer cases worldwide.

• Lucintel forecasts that, within the type category, epithelial type is expected to witness the highest growth over the forecast period.
• Within the application category, hospital and clinics is expected to witness a higher growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Circulating Tumor Cell Detection Kit Market

The circulating tumor cell (CTC) detection kit market is experiencing rapid transformation driven by technological advancements and evolving clinical needs. As the demand for early cancer diagnosis and personalized treatment rises, several trends are emerging that promise to shape the future of this sector.

• Integration of Artificial Intelligence: The integration of artificial intelligence (AI) into CTC detection is revolutionizing data analysis. AI algorithms enhance the accuracy of CTC identification and characterization, enabling faster and more reliable results. This technology assists clinicians in interpreting complex data, ultimately leading to better patient outcomes and personalized treatment strategies.
• Advancements in Microfluidics: Microfluidics technology is gaining traction in the CTC detection kit market. By allowing the manipulation of tiny volumes of fluids, these systems improve the capture and analysis of circulating tumor cells with higher efficiency and sensitivity. This trend is paving the way for portable point-of-care testing solutions that can provide timely diagnostic information.
• Development of Liquid Biopsies: Liquid biopsies, which analyze biomarkers from bodily fluids, are becoming more prevalent in CTC detection. These minimally invasive procedures allow for continuous monitoring of cancer progression and treatment response. This trend is facilitating personalized medicine by enabling oncologists to tailor therapies based on real-time data from CTCs.
• Focus on Multi-Omics Approaches: The trend toward multi-omics approaches-integrating genomics, proteomics, and metabolomics-is enhancing the understanding of tumor biology. This holistic view allows for the comprehensive profiling of CTCs, providing deeper insights into tumor heterogeneity and aiding in the development of targeted therapies that can address specific patient needs.
• Regulatory Support and Collaboration: Growing regulatory support is encouraging innovation in the CTC detection market. Agencies are streamlining approval processes for new diagnostic kits and fostering collaboration between academia and industry. This trend is essential for accelerating the development of cutting-edge technologies and bringing effective solutions to market more quickly.

The circulating tumor cell detection kit market is poised for significant growth as emerging trends like AI integration, microfluidics advancements, and regulatory support shape its future, ultimately enhancing cancer diagnostics and treatment.

Recent Developments in the Circulating Tumor Cell Detection Kit Market

The circulating tumor cell (CTC) detection kit market is rapidly evolving, fueled by advancements in technology and increasing demand for effective cancer diagnostics. Recent developments are enhancing the capabilities of CTC detection kits, making them more efficient, accurate, and accessible for clinical use.

• FDA Approvals for Innovative Kits: The U.S. Food and Drug Administration (FDA) has recently approved several new CTC detection kits that incorporate advanced technologies. These innovations focus on increasing the sensitivity and specificity of CTC detection, enabling healthcare providers to monitor cancer progression more effectively and tailor treatments based on individual patient profiles.
• Emergence of Point-of-Care Solutions: A new wave of point-of-care CTC detection kits is entering the market, designed for use in outpatient settings. These kits utilize simplified protocols and portable technologies, allowing healthcare professionals to conduct tests quickly and efficiently. This development is particularly beneficial for resource-limited environments, improving access to crucial diagnostic tools.
• Partnerships for Technology Development: Collaborations between biotech companies and research institutions are driving technological advancements in CTC detection. Recent partnerships focus on integrating next-generation sequencing and advanced imaging techniques into existing kits. This synergy enhances the ability to detect rare tumor cells and provides more comprehensive information about tumor biology.
• Focus on Personalized Medicine: The market is witnessing a shift toward personalized medicine, with CTC detection kits being tailored to assess treatment responses in real-time. Recent developments emphasize the need for kits that can analyze multiple biomarkers simultaneously, enabling oncologists to adapt therapies based on the evolving characteristics of a patient's tumor.
• Global Expansion of CTC Technologies: Companies are expanding their CTC detection technologies into emerging markets, particularly in Asia and Latin America. This expansion is driven by increasing cancer rates and the need for advanced diagnostic tools. Recent efforts include collaborations with local distributors to ensure that innovative CTC detection kits reach healthcare providers in these regions.

Recent developments in the circulating tumor cell detection kit market reflect a dynamic landscape, with innovations in technology, partnerships, and a focus on personalized medicine driving improvements in cancer diagnostics and treatment accessibility.

Strategic Growth Opportunities for Circulating Tumor Cell Detection Kit Market

The circulating tumor cell (CTC) detection kit market presents numerous strategic growth opportunities fueled by technological advancements, rising cancer incidence, and a shift toward personalized medicine. Companies can capitalize on these trends to enhance their offerings and expand their market presence.

• Expansion into Emerging Markets: Emerging markets in Asia, Africa, and Latin America represent significant growth opportunities for CTC detection kits. Rising cancer rates and increased healthcare investments are driving demand for advanced diagnostic solutions. Companies can tap into these markets by forming local partnerships and adapting their products to meet regional needs, ensuring broader access to CTC technologies.
• Integration of Artificial Intelligence: The incorporation of artificial intelligence (AI) in CTC detection processes offers a transformative growth opportunity. AI can enhance data analysis and interpretation, making CTC identification faster and more accurate. Companies that develop AI-driven solutions can differentiate themselves and provide valuable insights to oncologists, facilitating better patient management and outcomes.
• Development of Combination Diagnostics: There is a growing trend toward developing combination diagnostic kits that integrate CTC detection with other biomarker assessments. This holistic approach can provide a more comprehensive view of a patient's tumor biology and response to treatment. Companies that innovate in this space can enhance the utility of their products, appealing to healthcare providers seeking more informative diagnostic tools.
• Focus on Research and Development: Investing in research and development is crucial for advancing CTC detection technologies. Companies that prioritize R&D can develop next-generation kits with improved sensitivity, specificity, and usability. This focus can lead to breakthroughs in liquid biopsy technologies, positioning firms as leaders in a rapidly evolving market.
• Regulatory Engagement for Faster Approvals: Engaging proactively with regulatory agencies can expedite the approval process for new CTC detection kits. Companies that navigate the regulatory landscape effectively can bring innovative products to market more quickly. This strategic engagement can also foster collaboration opportunities, enhancing the credibility and visibility of their offerings within the industry.

Strategic growth opportunities in the circulating tumor cell detection kit market, including expansion into emerging markets, AI integration, combination diagnostics, R&D investment, and regulatory engagement, position companies for success in a competitive and evolving landscape.

Circulating Tumor Cell Detection Kit Market Driver and Challenges

The circulating tumor cell (CTC) detection kit market is influenced by several key drivers that facilitate growth, along with challenges that companies must navigate. Understanding these factors is essential for stakeholders aiming to thrive in this competitive landscape.

The factors responsible for driving the circulating tumor cell detection kit market include:

• Rising Cancer Incidence: The increasing global incidence of cancer is a major driver for the CTC detection kit market. As more people are diagnosed with various types of cancer, there is a growing demand for effective diagnostic tools that enable early detection and monitoring. This heightened need encourages healthcare providers to adopt advanced CTC technologies, thus expanding market opportunities.
• Technological Advancements: Continuous innovations in technology, such as microfluidics and next-generation sequencing, are propelling the CTC detection market. These advancements enhance the sensitivity and specificity of detection kits, making them more reliable for clinical applications. Companies that leverage cutting-edge technologies can offer superior products, attracting both healthcare professionals and patients.
• Shift Toward Personalized Medicine: The growing trend toward personalized medicine is driving the demand for CTC detection kits. Oncologists are increasingly seeking tailored treatment plans based on individual patient profiles, and CTC analysis provides critical insights for these personalized approaches. This focus on customized treatment is creating lucrative opportunities for companies in the CTC detection space.
• Increasing Investment in Cancer Research: Significant investments in cancer research and development are further fueling the CTC detection market. Government agencies, private organizations, and pharmaceutical companies are dedicating resources to innovative cancer diagnostics, including CTC technologies. This influx of funding fosters collaboration and accelerates the development of new, effective diagnostic solutions
• Awareness of Liquid Biopsy Benefits: The growing awareness of the advantages of liquid biopsies is a crucial driver for the CTC detection kit market. Patients and healthcare providers recognize the benefits of non-invasive testing methods, which reduce the need for traditional tissue biopsies. As knowledge about liquid biopsies spreads, demand for CTC detection kits is expected to rise.

Challenges in the circulating tumor cell detection kit market are:

• High Costs of Technology: One of the significant challenges in the CTC detection kit market is the high cost associated with advanced technologies. Many CTC detection kits are priced at a premium due to the complexity of their development and manufacturing processes. This high cost can limit accessibility, particularly in resource-limited settings, affecting widespread adoption.
• Regulatory Hurdles: Navigating the regulatory landscape can pose challenges for companies seeking to launch new CTC detection products. Stringent approval processes and varying regulatory requirements across regions can delay time-to-market and increase operational costs. Companies must invest time and resources to ensure compliance with these regulations, impacting their competitiveness.
• Competition and Market Saturation: The increasing number of players entering the CTC detection market presents challenges related to competition and market saturation. As more companies offer similar products, distinguishing their offerings becomes critical. This competitive pressure can lead to price wars, impacting profit margins and necessitating ongoing innovation to maintain market relevance.

The circulating tumor cell detection kit market is driven by rising cancer incidence, technological advancements, personalized medicine trends, increased research investment, and awareness of liquid biopsy benefits while facing challenges such as high costs, regulatory hurdles, and intense competition.

List of Circulating Tumor Cell Detection Kit Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, circulating tumor cell detection kit companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the circulating tumor cell detection kit companies profiled in this report include-

• Menarini Silicon Biosystems
• ZHIHUI MEDICAL
• Watson Biotech
• NovoBiotechnology
• GENO
• BioMab
• STEMCELL Technologies

Circulating Tumor Cell Detection Kit by Segment

The study includes a forecast for the global circulating tumor cell detection kit market by type, application, and region.

Circulating Tumor Cell Detection Kit Market by Type [Analysis by Value from 2019 to 2031]:

• Epithelial Type
• Interstitial Type
• Epithelial-Mesenchymal Type

Circulating Tumor Cell Detection Kit Market by Application [Analysis by Value from 2019 to 2031]:

• Hospital
• Clinic
• Other

Circulating Tumor Cell Detection Kit Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Circulating Tumor Cell Detection Kit Market

The circulating tumor cell (CTC) detection kit market is evolving rapidly, driven by advancements in cancer diagnostics and a growing emphasis on early detection. Here is a look at recent developments in key countries.

• United States: The U.S. market is witnessing innovative breakthroughs, with the FDA approving several new CTC detection kits that enhance sensitivity and specificity. Companies are investing heavily in research and development, focusing on liquid biopsy technologies that allow for less invasive cancer monitoring and personalized treatment plans.
• China: The Chinese CTC detection market is expanding due to increasing healthcare investments and a rising cancer incidence. Local biotech firms are developing affordable kits tailored for domestic use, and collaborations with international companies are enhancing technology transfer and market access.
• Germany: Germany remains a leader in Europe for CTC technology, with significant advancements in microfluidics and digital imaging. German firms are focusing on integrating artificial intelligence into their detection kits, improving accuracy and workflow efficiency for clinical laboratories.
• India: In India, the CTC detection kit market is growing as awareness of cancer and early detection rises. Local startups are innovating cost-effective solutions for CTC detection, aiming to make advanced cancer diagnostics more accessible in both urban and rural areas.
• Japan: The Japanese market is characterized by a strong emphasis on precision medicine. Recent developments include partnerships between universities and private companies to enhance CTC detection methodologies integrating advanced technologies like next-generation sequencing to improve diagnostic capabilities.

Features of the Global Circulating Tumor Cell Detection Kit Market

Market Size Estimates: Circulating tumor cell detection kit market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Circulating tumor cell detection kit market size by type, application, and region in terms of value ($B).

Regional Analysis: Circulating tumor cell detection kit market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the circulating tumor cell detection kit market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the circulating tumor cell detection kit market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M&A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the circulating tumor cell detection kit market by type (epithelial type, interstitial type, and epithelial-mesenchymal type), application (hospital, clinic, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Circulating Tumor Cell Detection Kit Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Circulating Tumor Cell Detection Kit Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Circulating Tumor Cell Detection Kit Market by Type
  • 3.3.1: Epithelial Type
  • 3.3.2: Interstitial Type
  • 3.3.3: Epithelial-Mesenchymal Type
• 3.4: Global Circulating Tumor Cell Detection Kit Market by Application
  • 3.4.1: Hospital
  • 3.4.2: Clinic
  • 3.4.3: Other

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Circulating Tumor Cell Detection Kit Market by Region
• 4.2: North American Circulating Tumor Cell Detection Kit Market
  • 4.2.1: North American Market by Type: Epithelial Type, Interstitial Type, and Epithelial-Mesenchymal Type
  • 4.2.2: North American Market by Application: Hospital, Clinic, and Other
• 4.3: European Circulating Tumor Cell Detection Kit Market
  • 4.3.1: European Market by Type: Epithelial Type, Interstitial Type, and Epithelial-Mesenchymal Type
  • 4.3.2: European Market by Application: Hospital, Clinic, and Other
• 4.4: APAC Circulating Tumor Cell Detection Kit Market
  • 4.4.1: APAC Market by Type: Epithelial Type, Interstitial Type, and Epithelial-Mesenchymal Type
  • 4.4.2: APAC Market by Application: Hospital, Clinic, and Other
• 4.5: ROW Circulating Tumor Cell Detection Kit Market
  • 4.5.1: ROW Market by Type: Epithelial Type, Interstitial Type, and Epithelial-Mesenchymal Type
  • 4.5.2: ROW Market by Application: Hospital, Clinic, and Other

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Circulating Tumor Cell Detection Kit Market by Type
  • 6.1.2: Growth Opportunities for the Global Circulating Tumor Cell Detection Kit Market by Application
  • 6.1.3: Growth Opportunities for the Global Circulating Tumor Cell Detection Kit Market by Region
• 6.2: Emerging Trends in the Global Circulating Tumor Cell Detection Kit Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Circulating Tumor Cell Detection Kit Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Circulating Tumor Cell Detection Kit Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Menarini Silicon Biosystems
• 7.2: ZHIHUI MEDICAL
• 7.3: Watson Biotech
• 7.4: NovoBiotechnology
• 7.5: GENO
• 7.6: BioMab
• 7.7: STEMCELL Technologies